ES2367256T3 - Células presentadoras de antígeno, método para su preparación y su uso para vacunas contra el cáncer. - Google Patents
Células presentadoras de antígeno, método para su preparación y su uso para vacunas contra el cáncer. Download PDFInfo
- Publication number
- ES2367256T3 ES2367256T3 ES02791520T ES02791520T ES2367256T3 ES 2367256 T3 ES2367256 T3 ES 2367256T3 ES 02791520 T ES02791520 T ES 02791520T ES 02791520 T ES02791520 T ES 02791520T ES 2367256 T3 ES2367256 T3 ES 2367256T3
- Authority
- ES
- Spain
- Prior art keywords
- cells
- cmsp
- adhapi
- pwm
- act
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
- C12N5/0694—Cells of blood, e.g. leukemia cells, myeloma cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/13—B-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/06—Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/52—CD40, CD40-ligand (CD154)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/59—Lectins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/04—Immortalised cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| WOIT01/00419 | 2001-07-30 | ||
| PCT/IT2001/000419 WO2003012085A1 (en) | 2001-07-30 | 2001-07-30 | Antigen presenting cells, method for their preparation and their use for cancer vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2367256T3 true ES2367256T3 (es) | 2011-10-31 |
Family
ID=11133712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES02791520T Expired - Lifetime ES2367256T3 (es) | 2001-07-30 | 2002-07-25 | Células presentadoras de antígeno, método para su preparación y su uso para vacunas contra el cáncer. |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20030119187A1 (enExample) |
| EP (1) | EP1412485B1 (enExample) |
| JP (1) | JP2004536615A (enExample) |
| KR (1) | KR100916670B1 (enExample) |
| CN (1) | CN100591762C (enExample) |
| AT (1) | ATE505533T1 (enExample) |
| AU (1) | AU2002334387B2 (enExample) |
| BR (1) | BR0211520A (enExample) |
| CA (1) | CA2453522C (enExample) |
| DE (1) | DE60239741D1 (enExample) |
| DK (1) | DK1412485T3 (enExample) |
| ES (1) | ES2367256T3 (enExample) |
| HU (1) | HUP0401753A3 (enExample) |
| MX (1) | MXPA04000885A (enExample) |
| PL (1) | PL211907B1 (enExample) |
| WO (2) | WO2003012085A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003012085A1 (en) | 2001-07-30 | 2003-02-13 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Antigen presenting cells, method for their preparation and their use for cancer vaccines |
| US6982253B2 (en) | 2002-06-05 | 2006-01-03 | Supergen, Inc. | Liquid formulation of decitabine and use of the same |
| US7695725B2 (en) * | 2003-02-06 | 2010-04-13 | Aduro Biotech | Modified free-living microbes, vaccine compositions and methods of use thereof |
| ATE552843T1 (de) * | 2003-02-06 | 2012-04-15 | Aduro Biotech | Listerien deren eindringen in nicht-phagozytische zellen abgeschwächt ist, impfstoffe, die diese listerien enthalten und deren verwendungen |
| KR101173871B1 (ko) * | 2003-02-06 | 2012-08-16 | 앤저 테라퓨틱스 인코퍼레이티드 | 변형된 독립생존 미생물, 백신 조성물 및 그것의 사용방법 |
| DE10329240A1 (de) * | 2003-06-24 | 2005-01-20 | Epigenomics Ag | Verfahren zur Analyse des Cytosin-Methylierungsstatus von Cancer-Testis-Antigenen für eine individualisierte Immuntherapie |
| US7842289B2 (en) * | 2003-12-24 | 2010-11-30 | Aduro Biotech | Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof |
| CN1910284B (zh) * | 2004-01-20 | 2011-04-06 | 爱知县 | 由HLA-A2402-限制的Ep-CAM-特异的CTL识别的表位/肽及其应用 |
| JP4925033B2 (ja) * | 2004-02-03 | 2012-04-25 | 学校法人 久留米大学 | ストレス誘導抗アポトーシス分子（ｉｅｘ−１）由来ペプチド |
| US7250416B2 (en) | 2005-03-11 | 2007-07-31 | Supergen, Inc. | Azacytosine analogs and derivatives |
| WO2007011693A2 (en) | 2005-07-14 | 2007-01-25 | Medistem Laboratories, Inc. | Compositions of placentally-derived stem cells for the treatment of cancer |
| US7700567B2 (en) | 2005-09-29 | 2010-04-20 | Supergen, Inc. | Oligonucleotide analogues incorporating 5-aza-cytosine therein |
| GB0700058D0 (en) * | 2007-01-03 | 2007-02-07 | Scancell Aps | Anti-tumor vaccine based on normal cells |
| WO2011072088A2 (en) * | 2009-12-08 | 2011-06-16 | Wilson Wolf Manufacturing Corporation | Improved methods of cell culture for adoptive cell therapy |
| JP6082737B2 (ja) * | 2011-07-07 | 2017-02-15 | リサーチ キャンサー インスティテュート オブ アメリカＲｅｓｅａｒｃｈ Ｃａｎｃｅｒ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ａｍｅｒｉｃａ | がんを治療するためのシステム、方法、および製剤 |
| US8933078B2 (en) | 2011-07-14 | 2015-01-13 | Research Cancer Institute Of America | Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances |
| HUE042327T2 (hu) | 2011-08-30 | 2019-06-28 | Astex Pharmaceuticals Inc | Decitabin-származék készítmények |
| PT2914254T (pt) * | 2012-10-30 | 2020-04-02 | Mei Pharma Inc | Terapias de combinação para tratar cancros quimiorresistentes |
| US9562219B2 (en) | 2013-12-27 | 2017-02-07 | SOTIO a.s. | Cryopreservation of apoptotic cancer cells for use in immunotherapy against cancer |
| JP2018515421A (ja) * | 2015-05-22 | 2018-06-14 | ブライアン ジェイ ツェルニキＣＺＥＲＮＩＥＣＫＩ， Ｂｒｉａｎ， Ｊ． | 複数用量注射準備済樹状細胞ワクチンの製造 |
| WO2017004538A1 (en) | 2015-07-02 | 2017-01-05 | Otsuka Pharmaceutical Co., Ltd. | Lyophilized pharmaceutical compositions |
| CN105132371B (zh) * | 2015-07-24 | 2016-05-25 | 北京鼎成肽源生物技术有限公司 | 体外提呈、激活dc细胞的方法及其应用 |
| US10052372B2 (en) * | 2016-05-24 | 2018-08-21 | Tessa Therapeutics Pte Ltd | T cell expansion |
| WO2018157081A1 (en) | 2017-02-27 | 2018-08-30 | Research Cancer Institute Of America | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms |
| WO2018170457A1 (en) | 2017-03-17 | 2018-09-20 | Research Cancer Institute Of America | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms |
| BR112020002280A2 (pt) | 2017-08-03 | 2020-07-28 | Otsuka Pharmaceutical Co., Ltd. | composto farmacológico e métodos purificação do mesmo |
| CN107557333B (zh) * | 2017-10-16 | 2018-07-31 | 北京鼎成肽源生物技术有限公司 | 一种用于细胞治疗的新抗原呈递细胞的制备方法 |
| WO2019099750A1 (en) | 2017-11-17 | 2019-05-23 | Research Cancer Institute Of America | Compositions, methods, systems and/or kits for preventing and/or treating neoplasms |
| KR102319259B1 (ko) | 2019-07-26 | 2021-10-28 | 정재웅 | 지반천공기용 확장리더 안전제어장치 |
| WO2021027057A1 (zh) * | 2019-08-15 | 2021-02-18 | 成都冕康生物科技有限公司 | 一种针对ebv病毒抗原的b细胞疫苗及其制备方法 |
| CN114099655A (zh) * | 2021-11-16 | 2022-03-01 | 苏州大学 | 一种预防或治疗癌症的疫苗系统及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1185811A (zh) * | 1995-03-31 | 1998-06-24 | H·沃尔夫 | 依赖于逆转录病毒样颗粒的抗原呈递系统 |
| NZ503334A (en) * | 1997-09-15 | 2002-05-31 | Genetic Immunity Llc | A gene delivering complex having a vector with a specific affinity for a foreign genetic material and a second site having a specific affinity for a receptor on an antigen presenting cell |
| US6613753B2 (en) | 2001-02-21 | 2003-09-02 | Supergen, Inc. | Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation |
| WO2003012085A1 (en) | 2001-07-30 | 2003-02-13 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Antigen presenting cells, method for their preparation and their use for cancer vaccines |
-
2001
- 2001-07-30 WO PCT/IT2001/000419 patent/WO2003012085A1/en not_active Ceased
- 2001-10-18 US US09/981,239 patent/US20030119187A1/en not_active Abandoned
-
2002
- 2002-07-25 AT AT02791520T patent/ATE505533T1/de not_active IP Right Cessation
- 2002-07-25 JP JP2003517263A patent/JP2004536615A/ja active Pending
- 2002-07-25 AU AU2002334387A patent/AU2002334387B2/en not_active Expired
- 2002-07-25 MX MXPA04000885A patent/MXPA04000885A/es active IP Right Grant
- 2002-07-25 BR BR0211520-4A patent/BR0211520A/pt not_active Application Discontinuation
- 2002-07-25 US US10/485,351 patent/US7883889B2/en not_active Expired - Lifetime
- 2002-07-25 KR KR1020047001217A patent/KR100916670B1/ko not_active Expired - Fee Related
- 2002-07-25 HU HU0401753A patent/HUP0401753A3/hu unknown
- 2002-07-25 PL PL367617A patent/PL211907B1/pl unknown
- 2002-07-25 DK DK02791520.6T patent/DK1412485T3/da active
- 2002-07-25 CA CA2453522A patent/CA2453522C/en not_active Expired - Lifetime
- 2002-07-25 WO PCT/IT2002/000488 patent/WO2003012086A1/en not_active Ceased
- 2002-07-25 EP EP02791520A patent/EP1412485B1/en not_active Expired - Lifetime
- 2002-07-25 ES ES02791520T patent/ES2367256T3/es not_active Expired - Lifetime
- 2002-07-25 CN CN02815007A patent/CN100591762C/zh not_active Expired - Lifetime
- 2002-07-25 DE DE60239741T patent/DE60239741D1/de not_active Expired - Lifetime
-
2004
- 2004-07-26 US US10/898,187 patent/US20050002920A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20050002920A1 (en) | 2005-01-06 |
| HK1068913A1 (zh) | 2005-05-06 |
| ATE505533T1 (de) | 2011-04-15 |
| MXPA04000885A (es) | 2004-06-03 |
| PL211907B1 (pl) | 2012-07-31 |
| WO2003012086A1 (en) | 2003-02-13 |
| BR0211520A (pt) | 2004-09-14 |
| JP2004536615A (ja) | 2004-12-09 |
| HUP0401753A2 (hu) | 2004-11-29 |
| EP1412485A1 (en) | 2004-04-28 |
| EP1412485B1 (en) | 2011-04-13 |
| CA2453522A1 (en) | 2003-02-13 |
| AU2002334387B2 (en) | 2007-10-04 |
| WO2003012085A1 (en) | 2003-02-13 |
| KR100916670B1 (ko) | 2009-09-08 |
| US20040185563A1 (en) | 2004-09-23 |
| CN1537161A (zh) | 2004-10-13 |
| DE60239741D1 (de) | 2011-05-26 |
| US20030119187A1 (en) | 2003-06-26 |
| US7883889B2 (en) | 2011-02-08 |
| PL367617A1 (en) | 2005-03-07 |
| CA2453522C (en) | 2013-04-30 |
| HUP0401753A3 (en) | 2011-04-28 |
| KR20040021662A (ko) | 2004-03-10 |
| DK1412485T3 (da) | 2011-08-01 |
| CN100591762C (zh) | 2010-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7883889B2 (en) | Antigen presenting cells, method for their preparation and their use for cancer vaccines | |
| AU2002334387A1 (en) | Antigen presenting cells, method for their preparation and their use for cancer vaccines | |
| ES2335396T3 (es) | Composicion farmaceutica para inducir una respuesta inmune en un ser humano o animal. | |
| ES2613132T3 (es) | Vacunas terapéuticas contra el cáncer derivadas de una línea celular dendrítica novedosa | |
| ES2621406T3 (es) | Método de inducción y de aceleración de células | |
| US20100303868A1 (en) | Ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases | |
| JP2001522226A (ja) | セミ−同種異系細胞での癌の免疫療法 | |
| MXPA03010254A (es) | Metodo de terapia celular para el tratamiento de tumores. | |
| MXPA03007503A (es) | Un metodo de terapia de celulas para el tratamiento de tumores. | |
| Ohtake et al. | Identification of novel helper epitope peptides of Survivin cancer-associated antigen applicable to developing helper/killer-hybrid epitope long peptide cancer vaccine | |
| WO2000057705A1 (en) | In vitro induction of antigen-specific t-cells using dendritic cell-tumor cell or dendritic cell-viral cell derived immunogens | |
| Kalady et al. | Dendritic cells pulsed with pancreatic cancer total tumor RNA generate specific antipancreatic cancer T cells | |
| WO2002053176A2 (en) | An autologous anti-cancer vaccine | |
| Shin et al. | Antitumor effect of intratumoral administration of dendritic cell combination with vincristine chemotherapy in a murine fibrosarcoma model | |
| JP6903866B2 (ja) | 血液由来単球の増殖誘導方法 | |
| Yamasaki et al. | Presentation of synthetic peptide antigen encoded by the MAGE-1 gene by granulocyte/macrophage-colony-stimulating-factor-cultured macrophages from HLA-A1 melanoma patients | |
| US20050170503A1 (en) | In vitro induction of antigen-specific T-cells using dendritic cell-tumor cell or dendritic cell-viral cell derived immunogens | |
| HK1068913B (en) | Antigen presenting cells, method for their preparation and their use for cancer vaccines | |
| MXPA98007775A (en) | Methods to induce immune responses in a suj |